<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Experimental and Clinical Surgery</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Experimental and Clinical Surgery</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник экспериментальной и клинической хирургии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2070-478X</issn><issn publication-format="electronic">2409-143X</issn><publisher><publisher-name xml:lang="en">Voronezh State Medical University named after N.N. Burdenko</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1574</article-id><article-id pub-id-type="doi">10.18499/2070-478X-2022-15-3-232-235</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Experience</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Опыт работы (архивный)</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">High-Dose Brachytherapy in Chemoradiation Schemes of Patients with Oral Mucosa Cancer</article-title><trans-title-group xml:lang="ru"><trans-title>Использование высокодозной брахитерапии в схемах химиолучевого лечения больных раком слизистой дна полости рта</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1333-5638</contrib-id><contrib-id contrib-id-type="spin">3883-6042</contrib-id><name-alternatives><name xml:lang="en"><surname>Moshurov</surname><given-names>Ivan Petrovich</given-names></name><name xml:lang="ru"><surname>Мошуров</surname><given-names>Иван Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>M.D., prof., Head of Department of Oncology N.N. Burdenko Voronezh State Medical University</p></bio><bio xml:lang="ru"><p>д.м.н., проф., заведующий кафедрой онкологии ВГМУ им.Н.Н. Бурденко</p></bio><email>moshurov@vokod.vrn.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0308-513X</contrib-id><contrib-id contrib-id-type="spin">2212-6667</contrib-id><name-alternatives><name xml:lang="en"><surname>Korotkikh</surname><given-names>Natalia Viktorovna</given-names></name><name xml:lang="ru"><surname>Коротких</surname><given-names>Наталия Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, Assistant, Department of Oncology</p></bio><bio xml:lang="ru"><p>к.м.н., ассистент, кафедра онкологии</p></bio><email>kornat78@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9774-9496</contrib-id><contrib-id contrib-id-type="spin">2478-7289</contrib-id><name-alternatives><name xml:lang="en"><surname>Kamenev</surname><given-names>Dmitry Yurievich</given-names></name><name xml:lang="ru"><surname>Каменев</surname><given-names>Дмитрий Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Candidate of Medical Sciences, Assistant, Department of Oncology</p></bio><bio xml:lang="ru"><p>к.м.н., ассистент, кафедра онкологии</p></bio><email>kamenev_dmitrii@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3504-9301</contrib-id><contrib-id contrib-id-type="spin">8339-8868</contrib-id><name-alternatives><name xml:lang="en"><surname>Tsurikova</surname><given-names>Anastasia Vladimirovna</given-names></name><name xml:lang="ru"><surname>Цурикова</surname><given-names>Анастасия Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Head of Radiotherapy Department №1</p></bio><bio xml:lang="ru"><p>заведующая радиотерапевтическим отделением №1</p></bio><email>anastasiyacurikova@yandex.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0991-9374</contrib-id><contrib-id contrib-id-type="spin">2500-0526</contrib-id><name-alternatives><name xml:lang="en"><surname>Kulikova</surname><given-names>Irina Nikolaevna</given-names></name><name xml:lang="ru"><surname>Куликова</surname><given-names>Ирина Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Radiotherapist, Radiotherapy Department No. 5</p></bio><bio xml:lang="ru"><p>врач-радиотерапевт, радитерапевтического отделения №5</p></bio><email>irakulikova68@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">FSBE HE «N.N. Burdenko Voronezh State Medical University» of the Ministry of Healthcare of the Russian Federation, Voronezh. Russia.</institution></aff><aff><institution xml:lang="ru">БУЗ ВО "ВОКОД", ВГМУ им. Н.Н. Бурденко</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">1. N.N. Burdenko Voronezh State Medical University, Voronezh. Russia.
2 Voronezh Regional Clinical Oncological Dispensary, Voronezh, Russia.</institution></aff><aff><institution xml:lang="ru">БУЗ ВО "ВОКОД", ВГМУ им. Н.Н. Бурденко, ВГМУ им. Н.Н.Бурденко МЗ РФ</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">BUZ VO VOKOD</institution></aff><aff><institution xml:lang="ru">БУЗ ВО "ВОКОД"</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-09-29" publication-format="electronic"><day>29</day><month>09</month><year>2022</year></pub-date><volume>15</volume><issue>3</issue><issue-title xml:lang="ru"/><fpage>232</fpage><lpage>235</lpage><history><date date-type="received" iso-8601-date="2022-02-21"><day>21</day><month>02</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-08-01"><day>01</day><month>08</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Voronezh N.N. Burdenko State Medical University</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Voronezh N.N. Burdenko State Medical University</copyright-holder><copyright-holder xml:lang="ru">ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnik-surgery.com/journal/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnik-surgery.com/journal/article/view/1574">https://vestnik-surgery.com/journal/article/view/1574</self-uri><abstract xml:lang="en"><p>The aim of the study was to improve clinical outcomes of oral mucosa cancer in case of surgical treatment failure.Materials and methods. A clinical case of combined radiation treatment of a patient with oral floor mucosa cancer St III T3N1M0 was presented. Pathogistological diagnosis # xxxxxx was: highly differentiated squamous cell carcinoma. A treatment plan was developed. Chemoradiotherapy at the first stage included 3 courses of intra-arterial chemotherapy (Selective (superselective) embolization (chemoembolization) of tumor vessels in the basin of the left and right facial and left lingual arteries, cisplatin 150 mg, combined with a daily infusion of 5-fluorouracil 4000 mg), with an interval 21 day. Chemoradiotherapy at the second stage included volume modulated arc therapy (VMAT) on the area of ​​the primary tumor (oral floor mucosa) and the regional metastasis pathways (total boost dose 60 Gy to the area of ​​regional lymph flow, otal boost dose 50 Gy to the oral cavity). Chemoradiotherapy at stage 3 included interstitial radiation therapy. A single boost dose (SBD) for the primary focus was 3 Gy/per fraction, 2 times a day, with an interval of 6 hours until total boost dose reached 21 Gy, 7 fractions.Results. After treatment, a complete regression of the tumor was noted. No pathological accumulation of radiopharmaceuticals, features of the tumor process was detected on PET/CT 48 months after treatment.Conclusions. Chemoradiotherapy combined with brachytherapy can be considered as an equal alternative to surgical treatment of patients with oral mucosa cancer.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель:</bold> улучшить результаты лечения рака слизистой дна полости рта при невозможности проведения хирургического лечения.</p> <p><bold>Материалы и методы</bold>: представлен клинический случай сочетанного лучевого лечения пациента с раком слизистой дна полости рта St III T3N1M0. ПГИ № ххххх: высокодифференцированный плоскоклеточный рак. Выработан план лечения: 1 этапом химиолучевое лечение: 3 курса внутриартериальной химиотерапии (Селективная (суперселективная) эмболизация (химиоэмболизация) опухолевых сосудов в бассейне левой и правой лицевой и левой язычной артерий цисплатин 150мг. На фоне суточной инфузии 5-фторурацила 4000 мг), с интервалом 21 день. 2 этапом - объемно модулированная лучевая терапия (VMAT) на область первичной опухоли (слизистая дна полости рта) и пути регионарного метастазирования (СОД 60 Гр на зоны регионарного лимфоотока, СОД 50 Гр на полость рта). 3 этапом – внутритканевая лучевая терапия. Разовая доза на первичный очаг составляла РОД 3Гр/за фракцию, 2 раза в день, с интервалом 6 часов до СОД 21Гр, 7 фракций.</p> <p><bold>Результаты</bold>: после проведенного лечения отмечен полный регресс опухоли. На ПЭТ/КТ через 48 месяцев после лечения патологического накопления РФП, характерного для опухолевого процесса не выявлено.</p> <p><bold>Выводы:</bold> Химиолучевое лечение в сочетании с брахитерапией может быть рассмотрено в качестве равноправной альтернативы хирургическому лечению больных с раком слизистой дна полости рта.</p></trans-abstract><kwd-group xml:lang="en"><kwd>brachytherapy</kwd><kwd>clinical case</kwd><kwd>oral mucosa cancer</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>брахитерапия</kwd><kwd>клинический случай</kwd><kwd>рак слизистой дна полости рта</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin AD, Starinsky VV, Shakhzadova AO. Zlokachestvennye novoоbrazovaniya v Rossii v 2019g (Zabolevaemost' i smertnost'). Moskva. 2020: 4. (in Russ.)</mixed-citation><mixed-citation xml:lang="ru">Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019г (Заболеваемость и смертность). Москва. 2020: 4.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Moshurov IP, Korotkov NV, Znatkova NA, Tsurikova AV, Ovechkina MV, Kamenev DYu, Kulikova IN, Meshcheryakova LS, Korotkov KN, Samodurov SS. Improving the clinical effectiveness of chemoradiotherapy of patients with cancer of the fundus of the mucous cavity. Issledovaniya i praktika v meditsine. 2018; 5: S2: 182. (in Russ.)</mixed-citation><mixed-citation xml:lang="ru">Мошуров И.П., Коротких Н.В., Знаткова Н.А., Цурикова А.В., Овечкина М.В., Каменев Д.Ю., Куликова И.Н., Мещерякова Л.С., Коротких К.Н., Самодуров С.С. Повышение клинической эффективности химиолучевого лечения больных раком дна слизистой полости. Исследования и практика в медицине. 2018. Т. 5. № S2. С. 182.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Kovács G. Modern head and neck brachytherapy: from radium towards intensity modulated interventional brachytherapy. J Contemp Brachytherapy. 2015;6(4):404-16. doi: 10.5114/jcb.2014.47813. </mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Torres-Quispe Percy, Fernández-Rodríguez Lissett Jeanette, Zhang Yaowen, Rovirosa-Casino Angeles. High dose interstitial brachytherapy for treatment of carcinoma of the lip as an alternative to surgery: a case report cancer. 2021; 15: 1297. https://doi.org/10.3332/ecancer.2021.1297</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Mazeron JJ, Ardiet JM, and Haie-Méder C. GEC-ESTRO recommendations for brachytherapy for head and neck squamous</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>cell carcinomas Radiother Oncol. 2009; 91: 150–156 https://doi.org/10.1016/j.radonc.2009.01.005 PMID: 19329209</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:1190–8</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Unetsubo T, Matsuzaki H, Takemoto M, Katsui K, Hara M, Katayama N. High-dose-rate brachytherapy using molds for lip and oral cavity tumors. Radiation Oncology. 2015; 10: 81. DOI 10.1186/s13014-015-0390-z</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Takácsi-Nagy Z, Martínez-Mongue R, Mazeron JJ, Anker CJ, Harrison. American Brachytherapy Society Task Group Report: Combined external beam irradiation and interstitial brachytherapy for base of tongue tumors and other head and neck sites in the era of new technologies. LB.Brachytherapy. 2017;16(1):44-58. doi: 10.1016/j.brachy.2016.07.005. Epub 2016 Aug 31. PMID: 27592129</mixed-citation></ref></ref-list></back></article>
